Categories: CauseDevelopmentManufacturingMedtechProductWebsite
Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing small-molecule kinase
Location: United States, Georgia, Vinings
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.01.2023 | - | $10M | - |
Mentions in press and media 7
| Date | Title | Description |
| 12.05.2025 | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line.
Milton Werner, Ph.D., is the founder and CEO of newly launched ABLi Therap... |
| 21.10.2024 | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 --
BOSTON and ATLANTA, Oct. 21, 2024 (GL... |
| 20.05.2024 | Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million | - |
| 07.03.2024 | Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders | - |
| 23.03.2023 | Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 | BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. IKT ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the cou... |
| 16.08.2021 | Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity | |
| 18.06.2021 | Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock | |
Reviews 0
